| Item 5.03 | Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year |
| Item 7.01 | Regulation FD Disclosure |
Effective August 20, 2019, HedgePath Pharmaceuticals, Inc. (the “Company”) filed an amendment to its certificate of incorporation, as amended, with the Secretary of State of Delaware to change its corporate name from “HedgePath Pharmaceuticals, Inc.” to “Inhibitor Therapeutics, Inc.” (the “Name Change Amendment”). The Name Change Amendment was previously approved by the Company’s board of directors and majority stockholder. The Name Change Amendment is filed as Exhibit 3.1 to this Current Report.
On August 19, 2019, the Company issued a press release regarding the change in its corporate name and also a change in the Company’s trading symbol from “HPPI” to “INTI”, effective with the opening of trading on August 20, 2019. A copy of such press release is filed as Exhibit 99.1 to this Current Report.
In addition, in light of the Company’s corporate name and ticker symbol change, attached as Exhibit 99.2 to this Current Report is an updated form of corporate presentation that the Company expects to use during future presentations by Company management. The information in Exhibit 99.2 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
| Item 9.01. | Financial Statements and Exhibits. |
Set forth below is a list of Exhibits included as part of this Current Report.
Cautionary Note on Forward-Looking Statements
This Current Report, the contents of Exhibits 99.1 and 99.2 to this Current Report, and any related statements of representatives and partners of the Company contain, or may contain, among other things, certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements with respect to the Company’s plans, objectives, projections, expectations and intentions and other statements identified by words such as “projects,” “may,” “will,” “could,” “would,” “should,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” or similar expressions. These statements are based upon the current beliefs and expectations of the Company’s management and are subject to significant risks and uncertainties, including those detailed in the Company’s filings with the Securities and Exchange Commission. Actual results (including, without limitation, the anticipated benefits of the new corporate name and ticker symbol, as well as the actual results of the Company’s anticipated future activities as described herein) may differ significantly from those set forth or implied in the forward-looking statements. These forward-looking statements involve numerous risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company’s control). The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
1
